Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.


POLIVY in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).1

 

POLIVY in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory (R/R) DLBCL who are not candidates for haematopoietic stem cell transplant.1

nil
Prescribing Information
Treatment pathway 1L: POLIVY
Discover where POLIVY can be used when treating patients with newly diagnosed DLBCL
Mechanism of action

POLIVY is a CD79b-targeted antibody-drug conjugate that delivers a potent anti-mitotic agent, monomethyl auristatin E (MMAE), directly to malignant B-cells.1



 

The molecule comprises MMAE covalently linked to a humanised IgG1 monoclonal antibody via a cleavable linker. The antibody binds with high affinity and selectivity to CD79b, a component of the B-cell receptor expressed on normal B-cells (except plasma cells) and malignant B-cells, including over 95% of diffuse large B-cell lymphomas.1



 

After binding, POLIVY is rapidly internalised, and the linker is cleaved by lysosomal proteases, releasing MMAE. MMAE binds to microtubules, blocking cell division and inducing apoptosis in dividing cells.1
Top resources
Polivy Product
Professor Graham Collins, Consultant Haematologist at Oxford University Hospital, shares his thoughts on the POLARIX 5-year PFS data
Polivy Product
Professor Graham Collins, Consultant Haematologist at Oxford University Hospital, shares his thoughts on the POLARIX 5-year safety data

We are dedicated to supporting HCPs to achieve optimal patient outcomes, If you have any questions about our products, from practical matters to understanding the data, please do not hesitate to contact us.

 

Contact our team to discuss POLIVY
Explore more
Polivy Product
Listen to the experts discuss the implications of the POLARIX trial data
Columvi Product
Explore the treatment landscape for DLBCL via our other promotional pages that include Roche products
Hematology Oncology Content page
Explore the Roche haematology portfolio


Abbreviations:


1L, first line; 2L, second line; 3L+, third line and beyond; BCL2, B-cell lymphoma 2 protein expression; BSH, British Society for Haematology; CNS, central nervous system; (D)LBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; EoT, end of treatment; GPP, good practice paper; HCP, healthcare professional; HGBCL, high-grade B-cell lymphoma; IgG, immunoglobulin G; IPI, International Prognostic Index; MDT, multidisciplinary team; MMAE, monomethyl auristatin E; MYC, myelocytomatosis oncogene; PET-CT, positron emission tomography-computed tomography; PFS, progression-free survival; R-CHP, rituximab, cyclophosphamide, doxorubicin, prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R/R, relapsed/refractory.

 

References:

  1. POLIVY Summary of Product Characteristics.
  2. Fox CP, et al. Br J Haematol. 2024;204(4):1178–1192.
  3. McKay P, et al. Br J Haematol. 2020;190(5):708–714.​
     
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. Adverse reactions should be reported by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.